Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shashikant Srivastava

Showing results (1-10 of 131) with videos related to

Pageof 14
Sort By:
Lung India : Official Organ of Indian Chest Society|July 17, 2015
Minimum inhibitory concentration, pharmacokinetics/pharmacodynamics and therapeutic drug monitoring: An integrated approach for multidrug-resistant tuberculosisShashikant Srivastava
Antimicrobial Agents and Chemotherapy|May 31, 2018
Clofazimine for the Treatment of Mycobacterium kansasiiShashikant Srivastava, Tawanda Gumbo
Current Pharmaceutical Design|August 13, 2011
In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimensShashikant Srivastava, Tawanda Gumbo
Microbiology Spectrum|April 21, 2026
Systematic and quantitative analyses of hollow fiber model of <i>Mycobacterium abscessus</i> lung disease studies and new dosing recommendationsShashikant Srivastava, Tawanda Gumbo
Idcases|July 17, 2023
Safety and tolerability of long-term use of omadacycline in the treatment of <i>Mycobacterium abscessus</i> infectionsShashikant Srivastava, Tawanda Gumbo
Open Forum Infectious Diseases|August 14, 2023
Comment on "Long-term Safety and Tolerability of Omadacycline for the Treatment of <i>Mycobacterium abscessus</i> Infections"Shashikant Srivastava, Tawanda Gumbo
International Journal of Antimicrobial Agents|December 14, 2023
It takes two to tango! Stability of drugs affecting efficacy against Mycobacterium abscessusSanjay Singh, Shashikant Srivastava
Antimicrobial Agents and Chemotherapy|February 25, 2018
Reply to Zimenkov, "Mutation in <i>luxR</i> Family Transcriptional Regulator Rv0890c Is Not a Marker of Linezolid Resistance"Shashikant Srivastava, Tawanda Gumbo
The European Respiratory Journal|January 2, 2014
Integrating drug concentrations and minimum inhibitory concentrations with Bayesian-dose optimisation for multidrug-resistant tuberculosisShashikant Srivastava, Tawanda Gumbo
The European Respiratory Journal|April 2, 2021
Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosisShashikant Srivastava, Tawanda Gumbo
Pageof 14

Showing results (1-10 of 131) with videos related to

Sort By:
Pageof 14
Lung India : Official Organ of Indian Chest Society|July 17, 2015
Minimum inhibitory concentration, pharmacokinetics/pharmacodynamics and therapeutic drug monitoring: An integrated approach for multidrug-resistant tuberculosisShashikant Srivastava
Antimicrobial Agents and Chemotherapy|May 31, 2018
Clofazimine for the Treatment of Mycobacterium kansasiiShashikant Srivastava, Tawanda Gumbo
Current Pharmaceutical Design|August 13, 2011
In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimensShashikant Srivastava, Tawanda Gumbo
Microbiology Spectrum|April 21, 2026
Systematic and quantitative analyses of hollow fiber model of <i>Mycobacterium abscessus</i> lung disease studies and new dosing recommendationsShashikant Srivastava, Tawanda Gumbo
Idcases|July 17, 2023
Safety and tolerability of long-term use of omadacycline in the treatment of <i>Mycobacterium abscessus</i> infectionsShashikant Srivastava, Tawanda Gumbo
Open Forum Infectious Diseases|August 14, 2023
Comment on "Long-term Safety and Tolerability of Omadacycline for the Treatment of <i>Mycobacterium abscessus</i> Infections"Shashikant Srivastava, Tawanda Gumbo
International Journal of Antimicrobial Agents|December 14, 2023
It takes two to tango! Stability of drugs affecting efficacy against Mycobacterium abscessusSanjay Singh, Shashikant Srivastava
Antimicrobial Agents and Chemotherapy|February 25, 2018
Reply to Zimenkov, "Mutation in <i>luxR</i> Family Transcriptional Regulator Rv0890c Is Not a Marker of Linezolid Resistance"Shashikant Srivastava, Tawanda Gumbo
The European Respiratory Journal|January 2, 2014
Integrating drug concentrations and minimum inhibitory concentrations with Bayesian-dose optimisation for multidrug-resistant tuberculosisShashikant Srivastava, Tawanda Gumbo
The European Respiratory Journal|April 2, 2021
Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosisShashikant Srivastava, Tawanda Gumbo
Pageof 14